Clinical Trials

Before any new treatment can be approved, it must first go through a prescribed series of clinical trials to assess first its safety and then its efficacy.

pipetting samplesThe mutually beneficial relationship between patients and research at the Anne Rowling Clinic provides an ideal platform to conduct clinical trials.

Below are the details of the clinical trials for which we are currently recruiting.

Please note that participation in any trial is entirely voluntary.

 

Clinical Trials Currently Enrolling

• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With SPMS (ASCEND in SPMS)

This study will investigate whether treatment with a drug called Natalizumab (Tysabri) slows down the accumulation of disability in people with secondary progressive MS. The aim is to recruit 10 patients by 13th February 2013. We are recruiting patients betweeen the ages of 18 and 58 inclusive who have had  secondary progressive MS for at least 2 years prior to enrollment in the study.

ClinicalTrials.gov Identifier: NCT01416181

Contact: neurologyclinicaltrials@biogenidec.com

 

Fully Enrolled Clinical Trials  / Recent Clinical Trials

• Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis (DECIDE)

This three-year study will try to determine if a drug called Daclizumab is more effective in the treatment of MS than a currently available treatment. It also aims to provide researchers with more information about the safety of the long-term treatment with the drug in people with MS. THIS STUDY IS FULLY ENROLLED.

ClinicalTrials.gov Identifier: NCT01064401